Empagliflozin improves blood pressure in patients with type 2 diabetes (T2DM) and hypertension

Background, methods: Efficacy, safety and tolerability of empagliflozin (EMPA) were investigated in patients with T2DM and hypertension in a randomized, double-blind Phase III trial. Patients received EMPA 10 mg (n = 276), 25 mg (n = 276) or placebo (PBO; n = 272) qd for 12 weeks. Co-primary endpoints were changes from baseline in HbA1c and mean 24-hour systolic blood pressure (SBP) by ambulatory BP monitoring (ABPM) at week 12. Key secondary endpoint was change from baseline in mean 24-hour diastolic BP (DBP) at week 12. Other secondary endpoints included changes from baseline in office SBP and DBP and proporti…